Celyad Oncology (XBRU:CYAD) EV-to-EBIT : -0.65 (As of May. 02, 2024)

Celyad Oncology EV-to-EBIT Chart

Celyad Oncology Annual Data
	Trend	Dec13	Dec14	Dec15	Dec16	Dec17	Dec18	Dec19	Dec20	Dec21	Dec22
EV-to-EBIT		Get a 7-Day Free Trial					-4.02	-3.54	-4.69	-1.98	0.02

Celyad Oncology Quarterly Data
	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Dec22	Jun23
EV-to-EBIT	Get a 7-Day Free Trial															-1.98	-1.20	-1.06	0.02	-

Competitive Comparison of Celyad Oncology's EV-to-EBIT

For the Biotechnology subindustry, Celyad Oncology's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Celyad Oncology's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Celyad Oncology's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Celyad Oncology's EV-to-EBIT falls into.

Celyad Oncology EV-to-EBIT Calculation

Celyad Oncology's EV-to-EBIT for today is calculated as:

Celyad Oncology's current Enterprise Value is €9.02 Mil.
Celyad Oncology's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €-13.93 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Celyad Oncology  (XBRU:CYAD) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Celyad Oncology's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2023 is calculated as:

Celyad Oncology's Enterprise Value for the quarter that ended in Jun. 2023 was €7.35 Mil.
Celyad Oncology's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €-13.93 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Celyad Oncology EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Celyad Oncology's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Celyad Oncology (XBRU:CYAD) Business Description